XML 47 R37.htm IDEA: XBRL DOCUMENT v3.7.0.1
Note 8 - Acquisition of EGEN, Inc. (Details Textual) - USD ($)
3 Months Ended 12 Months Ended
Aug. 02, 2016
Jun. 20, 2014
Mar. 31, 2017
Mar. 31, 2016
Dec. 31, 2016
Gain (Loss) from Valuation of Milestone Liability     $ (283,751) $ (302,656) $ 700,000
Finite-Lived Intangible Assets, Net     966,095   1,022,924
Noncompete Agreements [Member]          
Finite-Lived Intangible Assets, Accumulated Amortization     625,119   568,290
Amortization of Intangible Assets     56,829    
Finite-Lived Intangible Assets, Net     966,095   1,022,924
Indefinite-lived in Process Research and Development [Member]          
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)         1,400,000
EGEN Inc [Member]          
Business Combination, Consideration Transferred   $ 27,600,000      
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High   30,400,000 $ 30,400,000    
Payments to Acquire Businesses, Gross   $ 3,000,000      
Stock Issued During Period, Shares, Acquisitions   2,712,188      
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares 670,070        
Goodwill, Acquired During Period   $ 2,000,000      
EGEN Inc [Member] | Noncompete Agreements [Member]          
Finite-lived Intangible Assets Acquired         $ 1,600,000
Finite-Lived Intangible Asset, Useful Life         7 years
EGEN Inc [Member] | Indefinite-lived in Process Research and Development [Member]          
Indefinite-lived Intangible Assets Acquired   25,800,000      
EGEN Inc [Member] | Ovarian Cancer Study Milestone [Member]          
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High $ 12,400,000        
EGEN Inc [Member] | Glioblastoma Multiforme Brain Cancer Study Milestone [Member]          
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High 12,000,000        
EGEN Inc [Member] | TheraSilence Technology Milestone [Member]          
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High $ 6,000,000        
EGEN Inc [Member] | Maximum [Member]          
Business Combination, Consideration Transferred   $ 44,400,000